Antiparasitic Drugs Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 24.61 Billion |
| Market Size (2029) | USD 32.20 Billion |
| CAGR (2024 - 2029) | 5.53 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Antiparasitic Drugs Market Analysis
The Global Antiparasitic Drugs Market size is estimated at USD 24.61 billion in 2024, and is expected to reach USD 32.20 billion by 2029, growing at a CAGR of 5.53% during the forecast period (2024-2029).
The antiparasitic drugs market is a crucial pharmaceutical industry segment, primarily focused on medications that treat infections caused by parasites such as worms, protozoa, and ectoparasites. The significant factors contributing to the growth of the antiparasitic drugs market include the increasing prevalence of parasitic infections, the surge in research and development activities of companies to launch antiparasitic drugs, and the initiatives taken by the government and non-profit groups to raise public awareness regarding parasitic infections and provide appropriate treatment.
For instance, according to the World Health Organization (WHO) updates from April 2024, globally, an estimated 6–7 million individuals, predominantly in Latin America, are infected with Trypanosoma cruzi, the parasite responsible for Chagas disease. While Chagas disease is gaining a more prominent global presence, it remains primarily concentrated in 21 endemic countries across continental Latin America. In addition, as per the same source, about 75 million individuals are identified as being at risk of Trypanosoma cruzi infection. This shows the significant high parasitic disease burden, which is expected to boost market growth over the study period.
In addition, the positive recommendations of the regulators for new antiparasitic drugs are expected to increase the usage of these products in the market. For instance, in February 2024, the European Medicines Agency (EMA) issued a favorable opinion for Fexinidazole Winthrop, marking it as one of the oral treatments for rhodesiense sleeping sickness caused by Trypanosoma brucei rhodesiense. These positive opinions may increase the demand for treating parasitic infections, boosting market growth over the forecast period.
However, the adverse effects and risks associated with antiparasitic drugs are expected to hamper the growth of the antiparasitic drugs market over the forecast period.
Antiparasitic Drugs Market Trends
The Antiprotozoals Segment is Expected to Witness Growth in the Market Over the Forecast Period
Antiprotozoal drugs are medications designed to treat infections caused by protozoa, which are single-celled parasites. These drugs target protozoal diseases such as malaria, amoebiasis, giardiasis, leishmaniasis, and trypanosomiasis. The drugs work by inhibiting the growth or reproduction of the protozoa, thereby clearing the infection from the host. Factors such as a rise in protozoal infections, advanced drug development, and rising awareness about these infections are likely to boost the segment's growth over the forecast period.
Among the five Plasmodium parasites that cause malaria in humans, P. falciparum and P. vivax are the most significant threats. Hence, the high burden of malaria cases is expected to increase the demand for antiprotozoal drugs. For instance, according to data published by the World Health Organization (WHO) in December 2023, 85 countries reported an estimated 249 million malaria cases worldwide in 2022. In addition, as per the same source, Africa accounted for approximately 94% of the world's malaria cases, underscoring its significant share of the global malaria burden in 2022. Hence, the high burden of malaria cases is expected to boost demand for treatment products, thereby encouraging segment growth.
Furthermore, the strategies by market players, such as product approvals and launches, are increasing the availability of antiprotozoal drugs in the market. For instance, in July 2024, GSK PLC and Medicines for Malaria Venture (MMV) rolled out tafenoquine, a single-dose medication to prevent Plasmodium vivax (P. vivax) malaria relapses. This drug, co-administered with chloroquine for a radical cure, made its debut in both Thailand and Brazil. In addition, as per the same source, with the backing of MMV, the health ministries of Thailand and Brazil conducted feasibility studies on the routine implementation of tafenoquine following point-of-care G6PD testing in their public health systems.
Therefore, the high burden of the protozoal infections and company activities are expected to boost the segment growth over the forecast period.
North America is Expected to Record a Significant Market Share Over the Forecast Period
North America is expected to hold a significant market share in the antiparasitic drugs market due to the increasing prevalence of various parasitic infections, growing awareness of these infections, a rising number of strategic initiatives undertaken by prominent players, and the surge in research and development activities in North America.
For instance, according to data published by the Centers for Disease Control and Prevention in July 2024, Los Angeles General Medical Center in California reported a troubling uptick in P. vivax cases since early 2023, particularly among immigrants from China crossing into the United States through its southern border. Hence, the growing cases of malaria in the United States are expected to increase the need for drugs, thereby boosting the market growth in the region.
Furthermore, advancements in drug development and new product launches in the region are expected to propel market growth over the study period. For instance, in May 2024, Jolt Health Inc., based in Canada, secured intellectual property rights to advance transdermal delivery technology for chloroquine and hydroxychloroquine. The company mainly concentrates on utilizing hydroxychloroquine in a transdermal patch, targeting patients with malaria who are often underserved. Hence, the new product developments, coupled with their launches, are expected to boost market growth in the region over the forecast period.
Therefore, the high burden of parasitic infections, advancements in drug development, and new product launches are expected to boost the market growth in North America over the forecast period.
Antiparasitic Drugs Industry Overview
The antiparasitic drugs market is fragmented, with several key players. Companies are investing in R&D to develop new drugs, improve existing treatments, and create combination therapies to address drug resistance and enhance efficacy. In addition, collaborations and alliances with research institutions and global health organizations help in drug development and distribution, particularly in underserved regions. Some key players in the market include F. Hoffmann-La Roche, Novartis AG, GSK PLC, Bayer AG, and Merck KGaA.
Antiparasitic Drugs Market Leaders
-
Merck KGaA
-
Novartis AG
-
F. Hoffmann-La Roche Ltd
-
Bayer AG
-
GSK plc
*Disclaimer: Major Players sorted in no particular order
Antiparasitic Drugs Market News
- July 2024: two partners of the Pediatric Praziquantel Consortium, Merck, and Brazil's Instituto de Tecnologia em Fármacos (Farmanguinhos/Fiocruz), entered a collaboration agreement. This partnership enabled Farmanguinhos/Fiocruz to emerge as the producer of the Consortium's innovative pediatric treatment for schistosomiasis, specifically targeting preschool children aged 3 months to 6 years.
- January 2024: Johnson & Johnson pledged to continue its worldwide donations of VERMOX Chewable (500 mg mebendazole chewable tablets), an intestinal worm treatment, until 2030.
Anti-Parasitic Drugs Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Parasitic Infections
4.2.2 Increasing Investment in Research and Development Activities
4.3 Market Restraints
4.3.1 Adverse Effects and Risks Associated with the Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - in USD)
5.1 By Drug Type
5.1.1 Anthelmintics
5.1.2 Antiprotozoals
5.1.3 Other Drug Types
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Injectable
5.2.3 Topical
5.3 By Distribution Channel
5.3.1 Hospital Pharmacy
5.3.2 Retail Pharmacy
5.3.3 Other Distribution Channels
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 GSK plc
6.1.2 Merck KGaA
6.1.3 Novartis AG
6.1.4 Bayer
6.1.5 F. Hoffmann-La Roche Ltd
6.1.6 Zydus Group
6.1.7 Sanofi
6.1.8 Mankind Pharma
6.1.9 Cipla Ltd
6.1.10 Ipca Laboratories Ltd
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Antiparasitic Drugs Industry Segmentation
As per the scope of the report, antiparasitic drugs are used to treat various parasitic diseases, such as those caused by parasitic fungi, protozoa, helminths, ectoparasites, and amoeba. These drugs target and attack the parasitic agents of various infections and destroy or restrain their growth and development.
The antiparasitic drugs market is segmented by drug type, route of administration, distribution channel, and geography. By drug type, the market is segmented into anthelmintics, antiprotozoals, and other drug types. By route of administration, the market is segmented into oral, injectable, and topical. By distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and other distribution channels. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers market sizes and forecasts in terms of value (USD) for the above segments.
| By Drug Type | |
| Anthelmintics | |
| Antiprotozoals | |
| Other Drug Types |
| By Route of Administration | |
| Oral | |
| Injectable | |
| Topical |
| By Distribution Channel | |
| Hospital Pharmacy | |
| Retail Pharmacy | |
| Other Distribution Channels |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Anti-Parasitic Drugs Market Research FAQs
How big is the Global Antiparasitic Drugs Market?
The Global Antiparasitic Drugs Market size is expected to reach USD 24.61 billion in 2024 and grow at a CAGR of 5.53% to reach USD 32.20 billion by 2029.
What is the current Global Antiparasitic Drugs Market size?
In 2024, the Global Antiparasitic Drugs Market size is expected to reach USD 24.61 billion.
Who are the key players in Global Antiparasitic Drugs Market?
Merck KGaA, Novartis AG, F. Hoffmann-La Roche Ltd, Bayer AG and GSK plc are the major companies operating in the Global Antiparasitic Drugs Market.
Which is the fastest growing region in Global Antiparasitic Drugs Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Antiparasitic Drugs Market?
In 2024, the North America accounts for the largest market share in Global Antiparasitic Drugs Market.
What years does this Global Antiparasitic Drugs Market cover, and what was the market size in 2023?
In 2023, the Global Antiparasitic Drugs Market size was estimated at USD 23.25 billion. The report covers the Global Antiparasitic Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Antiparasitic Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Antiparasitic Drugs Industry Report
Statistics for the 2024 Global Antiparasitic Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Antiparasitic Drugs analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
Global Antiparasitic Drugs Market Report Snapshots
